Curis (CUS1) Q3 2026 Earnings Report

The call was predominantly optimistic, driven by strong and consistent PCNSL response data, progress toward full enrollment and potential accelerated approval submissions, the upcoming CLL data readout, and a stated cash runway into 2027. The main negatives were the higher year-to-date net loss, limited cash balance, choppy enrollment in the ultra-orphan PCNSL indication, and the fact that CLL efficacy data remain pending.

Curis expects to be fully enrolled in the PCNSL registrational study by the end of 2027, with 10 to 15 more patients needed, and, assuming that happens, anticipates filing for NDA for the accelerated approval in 2028 after following patients for probably 6 months from last patient in; responses are typically obtained in the first few cycles, the hurdle is generally a 20% ORR, and only a couple of responses are needed in order to hit the hurdle. In CLL, the company remains on track to report initial clinical data by year-end, with 12 patients on study across 11 clinical sites, including patients on drug for 3 or 4 cycles and potentially some patients with data for only a cycle or 2. Based on its current operating plan, Curis believes its existing cash and cash equivalents, along with the financing from October, should enable it to fund existing operations into '27.